

 Early Warning System

IFC-51148

Hikma Bond



Quick Facts

Countries	Jordan
Financial Institutions	International Finance Corporation (IFC)
Status	Approved
Bank Risk Rating	B
Voting Date	2025-06-30
Borrower	Hikma Finance USA LLC
Sectors	Education and Health, Industry and Trade
Investment Type(s)	Loan
Investment Amount (USD)	\$ 100.00 million
Project Cost (USD)	\$ 500.00 million



Project Description

According to the Bank's website, IFC provided a financing package (the "Financing Package") to Hikma Finance USA LLC (the "Borrower"), a wholly owned subsidiary of Hikma. Proceeds of the IFC Loan (as defined below) and the Bond (as defined below) which, for the avoidance of doubt, is limited to IFC's subscription of US\$50 million in the Bond, will be used to support the Company's general corporate purposes including acquisitions, capital expenditure, working capital needs, and any investment in research and development in the Middle East region, as well as debt refinancing of the Group (the "Project").



Early Warning System Project Analysis

This is a Category B project according to IFC's Environmental and Social Sustainability Policy. Based on IFC's review, the proposed project will have limited adverse E&S impacts that are few, site specific, largely reversible, and readily addressed through existing mitigation measures and good international industry practices (GIIP).



Investment Description

- International Finance Corporation (IFC)

A subscription in the Borrower's US\$500 million bond, in which IFC played an anchoring role – processed under IFC project Hikma Bond.

IFC's Investment as Approved by the Board: Loan 100.00 million (USD)



Private Actors Description

Hikma Pharmaceuticals PLC is a pharmaceutical company incorporated in the United Kingdom (UK) and listed on the London Stock Exchange since November 2005.. While the Group was founded in Jordan in 1978, Hikma has expanded its footprint with successful operations across the Middle East and North Africa (MENA) region, North America and Europe with 29 manufacturing plants in 10 countries. Hikma is a long-standing IFC client since 1987 whereby support was primarily provided for the Company's investments in the MENA region.

Hikma Finance USA LLC is a wholly owned subsidiary of Hikma.



Private Actor 1	Private Actor 1 Role	Private Actor 1 Sector	Relation	Private Actor 2	Private Actor 2 Role	Private Actor 2 Sector
-	-	-	-	Hikma Finance USA LLC	Client	-
-	-	-	-	Hikma Pharmaceuticals PLC	Parent Company	-



Contact Information

Hikma Pharmaceuticals PLC

Ibrahim Omari

Associate Director

+962 6 580 3100

iomari@hikma.com

Hikma HQ, MENA, Al-Bayader, King Abdullah The Second Street, Facing Al-Ahli Club, Amman, Jordan

www.hikma.com

ACCESS TO INFORMATION

You can submit a request for information disclosure at: <https://disclosures.ifc.org/#/inquiries>

If you believe that your request for information from IFC has been unreasonably denied, or that this Policy has been interpreted incorrectly, you can submit a complaint at the link above to IFC's Access to Information Policy Advisor, who reports directly to IFC's Executive Vice President.

ACCOUNTABILITY MECHANISM OF IFC/MIGA

The Compliance Advisor Ombudsman (CAO) is the independent complaint mechanism and fact-finding body for people who believe they are likely to be, or have been, adversely affected by an IFC or MIGA- financed project. If you submit a complaint to the CAO, they may assist you in resolving a dispute with the company and/or investigate to assess whether the IFC is following its own policies and procedures for preventing harm to people or the environment. If you want to submit a complaint electronically, you can email the CAO at CAO@worldbankgroup.org You can learn more about the CAO and how to file a complaint at <http://www.cao-ombudsman.org>



Bank Documents

- [Environmental & Social Review Summary \(ESRS\)](#)



Other Related Projects

- IFC-51629 Hikma Loan 2025